Among them, only RRP9 was significantly upregulated in AML patients (Fig. 4A), whereas NOP16 and NOP56 showed no significant changes (Fig. S5A, B), and DDX21 was downregulated (Fig. S5C). This evidence concerns the gene RRP9 and acute myeloid leukemia.